Therapeutic potential of the sphingosine kinase 1 inhibitor, PF-543
Xueliang Yi, Xuemei Tang, Tianlong Li, Lin Chen, Hongli He, Xiaoxiao Wu, Chunlin Xiang, Min Cao, Zixiang Wang, Yi Wang, Yiping Wang, Xiaobo Huang
Abstract
PF-543 is a sphingosine kinase 1（SPHK1）inhibitor developed by Pfizer and is currently considered the most potent selective SPHK1 inhibitor. SPHK1 catalyses the production of sphingosine 1-phosphate (S1P) from sphingosine. It is the rate-limiting enzyme of S1P production, and there is substantial evidence to support a very important role for sphingosine kinase in health and disease. This review is the first to summarize the role and mechanisms of PF-543 as an SPHK1 inhibitor in anticancer, antifibrotic, and anti-inflammatory processes, providing new therapeutic leads and ideas for future research and clinical trials.